Why Advicenne's Kidney Disease Drug Reverted To Standard EU Review

The CEO of French firm Advicenne explains why the company did not win an accelerated EU assessment for its kidney disease drug ADV7103, and why it may well try again in future with another indication – and perhaps with other new drugs too.